Viridian Therapeutics (VRDN) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Viridian Therapeutics (VRDN) right now is Lumvoa launch and TED market share: Lumvoa is Viridian's first commercial product and its near-term value driver. Revenue (Q1 2026) is ~$0.1M. If that keeps playing out, the setup is favourable; the risk to it is viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. No one can predict where VRDN trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Viridian Therapeutics (VRDN) higher?
1. Lumvoa launch and TED market share
Lumvoa is Viridian's first commercial product and its near-term value driver. In pivotal trials it delivered a 70% proptosis responder rate in active TED and 56% in chronic TED versus single-digit placebo rates, and it is the first therapy labeled at approval for both active and chronic stages. How fast it converts that data into prescriptions against Amgen's established Tepezza is the key swing factor.
2. Subcutaneous elegrobart pipeline
Elegrobart is Viridian's follow-on TED candidate with positive REVEAL-1 and REVEAL-2 phase 3 topline data and a BLA submission anticipated in 2027. If it becomes an approved subcutaneous autoinjector option, it could broaden the franchise beyond the intravenous Lumvoa and address patient convenience, a dimension where competitors are also racing to develop under-the-skin formulations.
3. FcRn portfolio and pipeline expansion
Beyond TED, Viridian is advancing an FcRn-targeted portfolio (VRDN-006 and VRDN-008) into autoimmune indications, with a VRDN-006 development plan and early VRDN-008 healthy-volunteer data expected in 2026. This gives the company a second therapeutic area to diversify away from single-product concentration, though these programs are early and unproven.
4. Strong cash runway
With roughly $762 million in cash and short-term investments as of March 2026, Viridian has funding to support the Lumvoa launch and advance its pipeline. That balance sheet reduces near-term financing pressure, although continued large operating losses and potential future raises remain part of the picture for a company still building revenue.
What could weigh on VRDN?
Viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. Lumvoa faces direct competition from Amgen's Tepezza, an entrenched incumbent that is also developing a subcutaneous formulation, and launch uptake, pricing, reimbursement, and physician adoption are all uncertain. The company is concentrated in thyroid eye disease, a rare-disease market, so any safety signal, slow launch, or competitive setback would weigh heavily. Pipeline programs like elegrobart and the FcRn portfolio carry clinical and regulatory risk, and continued losses could eventually require additional capital that dilutes shareholders.
Where VRDN trades today
A forecast starts from where the stock actually is. These are VRDN's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for VRDN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a VRDN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the VRDN guide and whether VRDN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the VRDN outlook
The bottom line: what is driving Viridian Therapeutics (VRDN) is Lumvoa launch and TED market share, with revenue (q1 2026) at ~$0.1M. If that keeps playing out the setup is favourable; the risk is viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. No one can predict the price, so treat any VRDN forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around VRDN with Walnut
Use Viridian Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Viridian Therapeutics (VRDN)?
+
No one can reliably predict where VRDN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Viridian Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive VRDN higher?
+
The main growth drivers are Lumvoa launch and TED market share; Subcutaneous elegrobart pipeline; FcRn portfolio and pipeline expansion. Whether they play out is the real question, not a guaranteed path.
What are the risks to VRDN?
+
Viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. Lumvoa faces direct competition from Amgen's Tepezza, an entrenched incumbent that is also developing a subcutaneous formulation, and launch uptake, pricing, reimbursement, and physician adoption are all uncertain. The company is concentrated in thyroid eye disease, a rare-disease market, so any safety signal, slow launch, or competitive setback would weigh heavily. Pipeline programs like elegrobart and the FcRn portfolio carry clinical and regulatory risk, and continued losses could eventually require additional capital that dilutes shareholders.
Will VRDN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Viridian Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is VRDN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the VRDN "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.